Joseph Thome
Stock Analyst at TD Cowen
(1.41)
# 3,593
Out of 5,099 analysts
19
Total ratings
37.5%
Success rate
-6.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $74.10 | -14.98% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $5.92 | +68.92% | 1 | Oct 31, 2025 | |
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $64.67 | +46.90% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $84.39 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $32.60 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $484.86 | -17.50% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $28.67 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $28.62 | +18.80% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $4.33 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $1.82 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $43.44 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.62 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $149.26 | -12.90% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.37 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.59 | - | 1 | Nov 23, 2021 |
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $74.10
Upside: -14.98%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.92
Upside: +68.92%
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $64.67
Upside: +46.90%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $84.39
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $32.60
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $484.86
Upside: -17.50%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $28.67
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $28.62
Upside: +18.80%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $4.33
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.82
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $43.44
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.62
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $149.26
Upside: -12.90%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $9.37
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.59
Upside: -